Core Viewpoint - Merck's stock experienced a decline of approximately 3.8%, reaching a low of $83.3, marking a two-week low due to mixed third-quarter earnings results [1] Financial Performance - Adjusted earnings per share (EPS) for Merck were reported at $2.58, with revenue of $17.28 billion, both exceeding expectations [1] - Revenue from the cancer immunotherapy Keytruda grew by 10% year-over-year to $8.14 billion, slightly below the expected $8.24 billion [1] Guidance Adjustment - The company has lowered its full-year earnings forecast to reflect anticipated tariff costs and other declines, now expecting adjusted EPS to be between $8.93 and $8.98, down from the previous estimate of $8.87 to $8.97 [1]